Clinical assessment incorporating a personal genome

The Lancet

Volumn 375, Issue 9725, 2010, Pages 1525-1535

  Ashley, Euan A ^a   Butte, Atul J ^b   Wheeler, Matthew T ^a   Chen, Rong ^b   Klein, Teri E ^b   Dewey, Frederick E ^a   Dudley, Joel T ^b   Ormond, Kelly E ^b   Pavlovic, Aleksandra ^a   Morgan, Alexander A ^b   Pushkarev, Dmitry ^b   Neff, Norma F ^b   Hudgins, Louanne ^b   Gong, Li ^b   Hodges, Laura M ^b   Berlin, Dorit S ^b   Thorn, Caroline F ^b   Sangkuhl, Katrin ^b   Hebert, Joan M ^b   Woon, Mark ^b   Sagreiya, Hersh ^b   Whaley, Ryan ^b   Knowles, Joshua W ^a   Chou, Michael F ^e   Thakuria, Joseph V ^d,e   Rosenbaum, Abraham M ^e   Zaranek, Alexander Wait ^e   Church, George M ^e   Greely, Henry T ^c   Quake, Stephen R ^b   Altman, Russ B ^b   more..

^a STANFORD UNIVERSITY MEDICAL CENTER   (United States)

^b STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c STANFORD LAW SCHOOL   (United States)

^d MASSACHUSETTS GENERAL HOSPITAL   (United States)

^e HARVARD MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ATENOLOL; ATORVASTATIN; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CLOPIDOGREL; CLOZAPINE; CYTOCHROME P450; CYTOCHROME P450 2C19; CYTOCHROME P450 4F2; DESMOPLAKIN; FLUINDOSTATIN; GENOMIC DNA; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; INFLIXIMAB; LYSOPHOSPHATIDIC ACID; MEMBRANE PROTEIN; MERCAPTOPURINE; METFORMIN; METHOTREXATE; METOPROLOL; MEVINOLIN; MYOSIN BINDING PROTEIN C; MYOSIN BINDING PROTEIN C 3; PRAVASTATIN; SIMVASTATIN; TENOFOVIR; TRANSMEMBRANE PROTEIN 43; TROGLITAZONE; UNCLASSIFIED DRUG; UNINDEXED DRUG; VITAMIN K EPOXIDE REDUCTASE COMPLEX SUBUNIT 1; WARFARIN;

ADULT; ARTICLE; CASE REPORT; CORONARY ARTERY DISEASE; DISEASE PREDISPOSITION; ECHOCARDIOGRAPHY; ELECTROCARDIOGRAPHY; FAMILY HISTORY; GENE FREQUENCY; GENE MAPPING; GENE SEQUENCE; GENETIC ANALYSIS; GENETIC RISK; GENETIC VARIABILITY; GENOME; GENOTYPE; GENOTYPE ENVIRONMENT INTERACTION; HUMAN; LOSS OF FUNCTION MUTATION; MALE; NON INSULIN DEPENDENT DIABETES MELLITUS; OBESITY; OSTEOARTHRITIS; OXYGEN CONSUMPTION; PEDIGREE; PHARMACOGENOMICS; PRIORITY JOURNAL; SINGLE NUCLEOTIDE POLYMORPHISM; SINUS RHYTHM; SUDDEN DEATH;

EID: 77951589703     PISSN: 01406736     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0140-6736(10)60452-7     Document Type: Article

References (54)

1. Choi M., Scholl U.I., Ji W., et al. Genetic diagnosis by whole exome capture and massively parallel DNA sequencing. Proc Natl Acad Sci USA 106 (2009) 19096-19101
2. Ng S.B., Turner E.H., Robertson P.D., et al. Targeted capture and massively parallel sequencing of 12 human exomes. Nature 461 (2009) 272-276
3. Wheeler D.A., Srinivasan M., Egholm M., et al. The complete genome of an individual by massively parallel DNA sequencing. Nature 452 (2008) 872-876
4. Kim J.I., Ju Y.S., Park H., et al. A highly annotated whole-genome sequence of a Korean individual. Nature 460 (2009) 1011-1015
5. Levy S., Sutton G., Ng P.C., et al. The diploid genome sequence of an individual human. PLoS Biol 5 (2007) e254
6. Tucker T., Marra M., and Friedman J.M. Massively parallel sequencing: the next big thing in genetic medicine. Am J Hum Genet 85 (2009) 142-154
7. Pushkarev D., Neff N.F., and Quake S.R. Single-molecule sequencing of an individual human genome. Nat Biotechnol 27 (2009) 847-852
8. Ng P.C., and Henikoff S. SIFT: predicting amino acid changes that affect protein function. Nucleic Acids Res 31 (2003) 3812-3814
9. Stenson P.D., Mort M., Ball E.V., et al. The human gene mutation database: 2008 update. Genome Med 1 (2009) 13
10. Ramensky V., Bork P., and Sunyaev S. Human non-synonymous SNPs: server and survey. Nucleic Acids Res 30 (2002) 3894-3900
11. Tanaka M., Takeyasu T., Fuku N., et al. Mitochondrial genome single nucleotide polymorphisms and their phenotypes in the Japanese. Ann N Y Acad Sci 1011 (2004) 7-20
12. The Uniprot Consortium. The Universal Protein Resource (UniProt) 2009. Nucleic Acids Res 37 (2009) D169-D174
13. Jegga A.G., Gowrisankar S., Chen J., and Aronow B.J. PolyDoms: a whole genome database for the identification of non-synonymous coding SNPs with the potential to impact disease. Nucleic Acids Res 35 (2007) D700-D706
14. Klein T.E., Chang J.T., Cho M.K., et al. Integrating genotype and phenotype information: an overview of the PharmGKB project. Pharmacogenetics Research Network and Knowledge Base. Pharmacogenomics J 1 (2001) 167-170
15. Chasman D.I., Shiffman D., Zee R.Y., et al. Polymorphism in the apolipoprotein(a) gene, plasma lipoprotein(a), cardiovascular disease, and low-dose aspirin therapy. Atherosclerosis 203 (2009) 371-376
16. Luke M.M., Kane J.P., Liu D.M., et al. A polymorphism in the protease-like domain of apolipoprotein(a) is associated with severe coronary artery disease. Arterioscler Thromb Vasc Biol 27 (2007) 2030-2036
17. Evangelou E., Chapman K., Meulenbelt I., et al. Large-scale analysis of association between GDF5 and FRZB variants and osteoarthritis of the hip, knee, and hand. Arthritis Rheum 60 (2009) 1710-1721
18. Allen K.J., Gurrin L.C., Constantine C.C., et al. Iron-overload-related disease in HFE hereditary hemochromatosis. N Engl J Med 358 (2008) 221-230
19. Tomatsu S., Orii K.O., Fleming R.E., et al. Contribution of the H63D mutation in HFE to murine hereditary hemochromatosis. Proc Natl Acad Sci USA 100 (2003) 15788-15793
20. Hymes J., Stanley C.M., and Wolf B. Mutations in BTD causing biotinidase deficiency. Hum Mutat 18 (2001) 375-381
21. Rossi A., and Superti-Furga A. Mutations in the diastrophic dysplasia sulfate transporter (DTDST) gene (SLC26A2): 22 novel mutations, mutation review, associated skeletal phenotypes, and diagnostic relevance. Hum Mutat 17 (2001) 159-171
22. Pulkkinen L., Christiano A.M., Gerecke D., et al. A homozygous nonsense mutation in the beta 3 chain gene of laminin 5 (LAMB3) in Herlitz junctional epidermolysis bullosa. Genomics 24 (1994) 357-360
23. Calonge M.J., Gasparini P., Chillaron J., et al. Cystinuria caused by mutations in rBAT, a gene involved in the transport of cystine. Nat Genet 6 (1994) 420-425
24. van der Zwaag P.A., Jongbloed J.D., van den Berg M.P., et al. A genetic variants database for arrhythmogenic right ventricular dysplasia/cardiomyopathy. Hum Mutat 30 (2009) 1278-1283
25. Maron B.J., Niimura H., Casey S.A., et al. Development of left ventricular hypertrophy in adults in hypertrophic cardiomyopathy caused by cardiac myosin-binding protein C gene mutations. J Am Coll Cardiol 38 (2001) 315-321
26. Shattuck T.M., Valimaki S., Obara T., et al. Somatic and germ-line mutations of the HRPT2 gene in sporadic parathyroid carcinoma. N Engl J Med 349 (2003) 1722-1729
27. Cuppens H., Legius E., Cabello P., et al. Association between XV2c/CS7/KM19/D9 haplotypes and the delta F508 mutation. A study of 57 Belgian families. Hum Genet 85 (1990) 402-403
28. Morner S., Richard P., Kazzam E., et al. Identification of the genotypes causing hypertrophic cardiomyopathy in northern Sweden. J Mol Cell Cardiol 35 (2003) 841-849
29. Van Driest S.L., Vasile V.C., Ommen S.R., et al. Myosin binding protein C mutations and compound heterozygosity in hypertrophic cardiomyopathy. J Am Coll Cardiol 44 (2004) 1903-1910
30. Merner N.D., Hodgkinson K.A., Haywood A.F., et al. Arrhythmogenic right ventricular cardiomyopathy type 5 is a fully penetrant, lethal arrhythmic disorder caused by a missense mutation in the TMEM43 gene. Am J Hum Genet 82 (2008) 809-821
31. Yang Z., Bowles N.E., Scherer S.E., et al. Desmosomal dysfunction due to mutations in desmoplakin causes arrhythmogenic right ventricular dysplasia/cardiomyopathy. Circ Res 99 (2006) 646-655
32. Nishizato Y., Ieiri I., Suzuki H., et al. Polymorphisms of OATP-C (SLC21A6) and OAT3 (SLC22A8) genes: consequences for pravastatin pharmacokinetics. Clin Pharmacol Ther 73 (2003) 554-565
33. Kivistö K.T., and Niemi M. Influence of drug transporter polymorphisms on pravastatin pharmacokinetics in humans. Pharm Res 24 (2007) 239-247
34. SEARCH Collaborative Group, Link E., Parish S., Armitage J., et al. SLCO1B1 variants and statin-induced myopathy-a genomewide study. N Engl J Med 359 (2008) 789-799
35. Mega J.L., Close S.L., Wiviott S.D., et al. Cytochrome p-450 polymorphisms and response to clopidogrel. N Engl J Med 360 (2009) 354-362
36. Yuan H.Y., Chen J.J., Lee M.T., et al. A novel functional VKORC1 promoter polymorphism is associated with inter-individual and inter-ethnic differences in warfarin sensitivity. Hum Mol Genet 14 (2005) 1745-1751
37. Pérez-Andreu V., Roldán V., Antón A.I., et al. Pharmacogenetic relevance of CYP4F2 V433M polymorphism on acenocoumarol therapy. Blood 113 (2009) 4977-4979
38. Pacanowski M.A., Gong Y., Cooper-Dehoff R.M., et al., INVEST Investigators. Beta-adrenergic receptor gene polymorphisms and beta-blocker treatment outcomes in hypertension. Clin Pharmacol Ther 84 (2008) 715-721
39. Johnson J.A., Zineh I., Puckett B.J., McGorray S.P., Yarandi H.N., and Pauly D.F. Beta 1-adrenergic receptor polymorphisms and antihypertensive response to metoprolol. Clin Pharmacol Ther 74 (2003) 44-52
40. Couvert P., Giral P., Dejager S., et al. Association between a frequent allele of the gene encoding OATP1B1 and enhanced LDL-lowering response to fluvastatin therapy. Pharmacogenomics 9 (2008) 1217-1227
41. Lanfear D.E., Jones P.G., Marsh S., Cresci S., McLeod H.L., and Spertus J.A. Beta2-adrenergic receptor genotype and survival among patients receiving beta-blocker therapy after an acute coronary syndrome. JAMA 294 (2005) 1526-1533
42. Kaye D.M., Smirk B., Williams C., Jennings G., Esler M., and Holst D. Beta-adrenoceptor genotype influences the response to carvedilol in patients with congestive heart failure. Pharmacogenetics 13 (2003) 379-382
43. Rau T., Wuttke H., Michels L.M., et al. Impact of the CYP2D6 genotype on the clinical effects of metoprolol: a prospective longitudinal study. Clin Pharmacol Ther 85 (2009) 269-272
44. Moore A.F., Jablonski K.A., McAteer J.B., et al., Diabetes Prevention Program Research Group. Extension of type 2 diabetes genome-wide association scan results in the diabetes prevention program. Diabetes 57 (2008) 2503-2510
45. Capriotti E., Calabrese R., and Casadio R. Predicting the insurgence of human genetic diseases associated to single point protein mutations with support vector machines and evolutionary information. Bioinformatics 22 (2006) 2729-2734
46. Shuldiner A.R., O'Connell J.R., Bliden K.P., et al. Association of cytochrome P450 2C19 genotype with the antiplatelet effect and clinical efficacy of clopidogrel therapy. JAMA 302 (2009) 849-857
47. Klein T.E., Altman R.B., Eriksson N., et al. Estimation of the warfarin dose with clinical and pharmacogenetic data. N Engl J Med 360 (2009) 753-764
48. Caldwell M.D., Awad T., Johnson J.A., et al. CYP4F2 genetic variant alters required warfarin dose. Blood 111 (2008) 4106-4112
49. Jakobsdottir J., Gorin M.B., Conley Y.P., Ferrell R.E., and Weeks D.E. Interpretation of genetic association studies: markers with replicated highly significant odds ratios may be poor classifiers. PLoS Genet 5 (2009) e1000337
50. Kathiresan S., Melander O., Anevski D., et al. Polymorphisms associated with cholesterol and risk of cardiovascular events. N Engl J Med 358 (2008) 1240-1249
51. Genome-wide association study of 14,000 cases of seven common diseases and 3,000 shared controls. Nature 447 (2007) 661-678
52. Kamstrup P.R., Tybjaerg-Hansen A., Steffensen R., and Nordestgaard B.G. Pentanucleotide repeat polymorphism, lipoprotein(a) levels, and risk of ischemic heart disease. J Clin Endocrinol Metab 93 (2008) 3769-3776
53. Clarke R., Peden J.F., Hopewell J.C., et al. Genetic variants associated with Lp(a) lipoprotein level and coronary disease. N Engl J Med 361 (2009) 2518-2528
54. Grundy S.M., Cleeman J.I., Merz C.N., et al. Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III guidelines. Circulation 110 (2004) 227-239